AAN: phenytoin neuroprotective in optic neuritis

AAN: phenytoin neuroprotective in optic neuritis
Phenytoin appears to be neuroprotective in acute optic neuritis, according to a study scheduled to be presented at the annual meeting of the American Academy of Neurology, held from April 18 to 25 in Washington, D.C.

(HealthDay)—Phenytoin appears to be neuroprotective in acute optic neuritis (AON), according to a study scheduled to be presented at the annual meeting of the American Academy of Neurology, held from April 18 to 25 in Washington, D.C.

Raju Kapoor, M.D., from the National Hospital for Neurology and Neurosurgery in London, and colleagues conducted a phase 2 involving 81 patients with AON. Participants were randomized within two weeks of to receive phenytoin (39 patients) or placebo (42 patients) for three months. Using , the researchers assessed retinal nerve fiber layer (RNFL) thickness and macular volume (MV) at baseline and six months later.

The researchers found that at six months, the average adjusted affected eye RNFL thickness was 7.15 µm higher in the phenytoin group than the placebo group in intention-to-treat analysis, a 30 percent protective treatment effect. In the phenytoin group, adjusted MV was 0.2 mm³ higher, a 34 percent protective treatment effect. In per-protocol comparisons, similar significant treatment effects were observed. Vision generally recovered well with no significant between-group difference in visual outcomes.

"If this finding is confirmed by larger studies, it could lead to a treatment that may prevent nerve damage and blindness in multiple sclerosis, and could help other attacks of , serving a major unmet need," the authors write.

The study was partially funded by a grant from Novartis.

More information: Press Release
More Information

Copyright © 2015 HealthDay. All rights reserved.

Citation: AAN: phenytoin neuroprotective in optic neuritis (2015, April 17) retrieved 19 March 2024 from https://medicalxpress.com/news/2015-04-aan-phenytoin-neuroprotective-optic-neuritis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Experimental drug that may repair nerve damage in MS moves forward

17 shares

Feedback to editors